- Home
- INCY vs RNR Comparison
INCY vs RNR Comparison
Compare INCY & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- RNR
- Stock Information
- Founded
- INCY 1991
- RNR 1993
- Country
- INCY United States
- RNR Bermuda
- Employees
- INCY N/A
- RNR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- RNR Property-Casualty Insurers
- Sector
- INCY Health Care
- RNR Finance
- Exchange
- INCY Nasdaq
- RNR Nasdaq
- Market Cap
- INCY 13.4B
- RNR 11.8B
- IPO Year
- INCY 1993
- RNR 1995
- Fundamental
- Price
- INCY $68.46
- RNR $244.77
- Analyst Decision
- INCY Hold
- RNR Buy
- Analyst Count
- INCY 20
- RNR 12
- Target Price
- INCY $73.81
- RNR $283.45
- AVG Volume (30 Days)
- INCY 2.1M
- RNR 411.0K
- Earning Date
- INCY 07-29-2025
- RNR 07-23-2025
- Dividend Yield
- INCY N/A
- RNR 0.65%
- EPS Growth
- INCY N/A
- RNR N/A
- EPS
- INCY 0.10
- RNR 31.81
- Revenue
- INCY $4,413,226,000.00
- RNR $12,613,932,000.00
- Revenue This Year
- INCY $13.29
- RNR N/A
- Revenue Next Year
- INCY $10.47
- RNR $0.99
- P/E Ratio
- INCY $623.03
- RNR $7.69
- Revenue Growth
- INCY 17.13
- RNR 31.51
- 52 Week Low
- INCY $53.56
- RNR $208.98
- 52 Week High
- INCY $83.95
- RNR $300.00
- Technical
- Relative Strength Index (RSI)
- INCY 56.95
- RNR 50.09
- Support Level
- INCY $67.57
- RNR $242.21
- Resistance Level
- INCY $71.29
- RNR $248.28
- Average True Range (ATR)
- INCY 1.98
- RNR 5.54
- MACD
- INCY -0.13
- RNR -0.26
- Stochastic Oscillator
- INCY 61.55
- RNR 45.94
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.